logo
Ambient AI tools in health care: A new companion for clinicians

Ambient AI tools in health care: A new companion for clinicians

Ambient listening artificial intelligence (Ambient AI) is gaining traction in the clinical setting. Ambient AI tools passively 'listen' to conversations between clinicians and patients and, based on these conversations, automatically transcribe and summarize encounters.
Ambient AI has the potential to reduce the time that treating clinicians spend documenting patient encounters, which may reduce clinician burnout over time. Importantly, Ambient AI should enhance patient experience and improve the accuracy of patient encounter documentation.
Ambient AI systems typically rely on microphones integrated into smartphones, tablets or dedicated in-room devices. These systems use automatic speech recognition with natural language processing and machine-learning algorithms to extract relevant clinical information from a conversation. In many cases, the output is a draft clinical note or a structured data entry into the electronic health record system, without manual input from a clinician.
Legal and ethical considerations
Ambient AI tools involve unsettled questions of legal and ethical responsibility.
As covered entities under the Health Insurance Portability and Accountability Act (HIPAA), clinicians are responsible for implementing measures to maintain the privacy and security of protected health information (PHI). Clinicians must also ensure that their technology vendors, if they receive or maintain PHI on behalf of clinicians, also maintain the privacy and security of PHI. Therefore, clinicians must understand how an Ambient AI tool functions with respect to PHI to apply the appropriate privacy and security standards to the entity that provides the Ambient AI tool.
Another important threshold question is whether a clinician must inform patients that the clinician will use an Ambient AI tool to record conversations between the clinician and the patient.
Regardless of state law consent requirements for recording conversations, health care settings are unique environments that may mitigate in favor of disclosing the use of Ambient AI to patients.
Legal and ethical obligations related to informed consent, transparency and patient trust support the disclosure of the use of an Ambient AI tool. Clinicians should be ready to discuss how Ambient AI is utilized, appreciating that some patients may view the use of an Ambient AI tool to record conversations negatively and may withhold important medical information as a result.
Under HIPAA, a patient has a right to adequate notice of the uses and disclosures of PHI by a clinician. Clinicians satisfy this obligation by providing patients a notice of privacy practices (NPP). Current guidance does not specifically address Ambient AI and whether its use must be disclosed. That will likely change. Until then, clinicians must determine, based on how an Ambient AI tool interacts with PHI, whether the tool must be disclosed as part of the clinicians' NPPs.
Disclosure is the safest way to ensure compliance.
Best practices and compliance recommendations
Clinicians considering implementing an Ambient AI tool should:
Establish clear protocols to obtain patient consent to use the tool.
Understand how the Ambient AI tool functions in order to hold vendors to appropriate privacy and security standards.
Develop a fulsome audit strategy to continually monitor the accuracy of the Ambient AI tool's output.
expand
William P. Keefer, Partner and Co-Leader of Phillips Lytle's Health Care and Life Sciences Team, counsels hospitals, physician groups and other health care clients on a broad array of issues. He can be reached at wkeefer@phillipslytle.com or (716) 847-5488.
expand
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

1 Jaw-Dropping Stat Palantir Investors Must Know
1 Jaw-Dropping Stat Palantir Investors Must Know

Yahoo

timean hour ago

  • Yahoo

1 Jaw-Dropping Stat Palantir Investors Must Know

Palantir's artificial intelligence (AI) software has been popular for decades. The company's U.S. commercial revenue growth rate is impressive. The stock carries a hefty price tag. 10 stocks we like better than Palantir Technologies › Palantir's (NASDAQ: PLTR) stock has defied logic since its bull run began in 2024. The stock is up a mind-boggling 700% since the start of 2024, making anyone who invested in Palantir's stock and held on quite satisfied. While that's an impressive statistic, it's not the one I think investors should focus on. This statistic could make or break the Palantir investment thesis, and both potential Palantir buyers and current shareholders must be aware of its significance. Palantir is another company that's heavily investing in the artificial intelligence (AI) arms race. While most companies only started launching products in recent years, Palantir and its AI-powered data analytics platform have been doing it since the early 2000s, giving the company a leg up. Originally, its software was intended for government use and reportedly helped take down Osama bin Laden; it has also been used for other tasks, such as optimizing vaccine distribution during the COVID-19 pandemic. Eventually, management decided that there was a potential use case for Palantir's platform on the commercial side, and they were correct. Although government revenue still makes up the majority of Palantir's financial picture, commercial revenue also plays a big part. In Q1, the commercial side generated $397 million (up 33% year over year) versus the government sector's $487 million (up 45% year over year). Considering how mature the government side of its business is, it may come as a surprise that it outperformed the commercial side; however, this is primarily due to poor international performance on the commercial side. Outside the U.S. and China, the world has been fairly slow to adopt AI. For example, Palantir's U.S. commercial revenue increased 71% to $255 million in Q1. That's a significant mismatch from the overall commercial growth rate, especially when considering that U.S. revenue accounted for approximately two-thirds of total commercial revenue. If the rest of the world (specifically Europe) starts to adopt AI, Palantir's growth rate could accelerate to an even faster rate, which could send the stock rocketing higher. However, this isn't the key metric I think investors should be focusing on. Instead, investors need to examine Palantir's valuation and determine what assumptions are already reflected in the stock price. In Q1, Palantir's overall revenue rose 39% year over year. However, the stock has increased by over 700% since the start of 2024. Those two numbers are completely mismatched and suggest that Palantir's soaring valuation is more a result of its rising stock price than its actual business performance. When a stock becomes uncoupled from the business, that's a problem, and it could lead to issues with Palantir's stock moving forward. Currently, Palantir's stock trades at a jaw-dropping 112 times sales. Most software companies trade at a multiple of 10 to 20 times sales, so Palantir is significantly outside this range. Furthermore, this isn't the first time stock investors have seen a company trade for more than 100 times sales. However, most stocks that achieved that valuation were doubling or tripling the revenue year over year, and Palantir isn't anywhere close to that. I'd challenge investors to find a stock that has traded for more than 100 times sales (that didn't go public with little to no revenue) that has worked out for investors over the long term; I can't find any. Palantir has found itself in a problematic spot, and the only way forward is to grow its way into a higher valuation or suffer a painful stock price correction. For Palantir's stock to reach a more reasonable (but still very expensive 20 times sales), it would need to grow its revenue by more than 550%. At today's current 39% growth rate, that would take over five years of growth with the stock price staying flat. That would lead to disappointing returns for investors, so I think investors must be aware of the extreme valuation of Palantir's stock and take action. If you've ridden Palantir up, it's not a bad idea to sell some (or all) of your shares. If you're a prospective Palantir shareholder, I'd suggest steering clear, as there is just too much hype built into Palantir's stock for it to deliver solid long-term returns. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,477!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,010,880!* Now, it's worth noting Stock Advisor's total average return is 1,047% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of July 7, 2025 Keithen Drury has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. 1 Jaw-Dropping Stat Palantir Investors Must Know was originally published by The Motley Fool

Meta strengthens portfolio with PlayAI acquisition
Meta strengthens portfolio with PlayAI acquisition

Yahoo

timean hour ago

  • Yahoo

Meta strengthens portfolio with PlayAI acquisition

Facebook-parent Meta Platforms has reportedly acquired PlayAI, a startup specialising in AI-powered voice technology. The PlayAI team is scheduled to integrate into Meta week commencing 13 July 2025, Bloomberg reported citing an internal memo. They will report to Johan Schalkwyk, who joined Meta from another voice AI startup Sesame AI. Financial details of the acquisition were not divulged. However, a Meta spokesperson confirmed the deal to the publication without providing further details. PlayAI's AI Agent platform is designed to create conversational agents capable of understanding and responding to user inputs in a natural manner. The platform combines advanced language models with high-quality text-to-speech technology to facilitate human-like interactions. According to the internal memo, PlayAI's expertise in natural voice creation aligns well with Meta's objectives in AI Characters, Meta AI, Wearables, and audio content creation. The acquisition is also aligned with Meta's broader strategy to prioritise AI. The company is investing significantly in infrastructure, including chips and data centres, and is actively recruiting talent to develop AI models and features. Recently, Meta CEO Mark Zuckerberg, announced a restructuring of the company's AI division. The new unit, called Meta Superintelligence Labs led by former Scale AI CEO Alexandr Wang, will work to accelerate the development of artificial general intelligence and enhance Meta's revenue through AI applications, image-to-video advertising, and smart glasses. Meta also invested around €3bn ($3.5bn) earlier in July 2025 to acquire a nearly 3% stake in EssilorLuxottica, the eyewear manufacturer known for the Ray-Ban brand. The investment strengthened the ongoing collaboration between Meta and EssilorLuxottica on AI-enabled smart glasses. "Meta strengthens portfolio with PlayAI acquisition" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Musk's xAI plans funding round targeting up to $200bn
Musk's xAI plans funding round targeting up to $200bn

Yahoo

timean hour ago

  • Yahoo

Musk's xAI plans funding round targeting up to $200bn

Elon Musk's AI company, xAI, is reportedly targeting a valuation between $170bn and $200bn in its next funding round. This potential valuation comes amidst discussions with Saudi Arabia's Public Investment Fund (PIF), according to sources cited by the Financial Times. The sovereign wealth fund holds an indirect stake in xAI through Kingdom Holdings' $800m investment. However, the discussions are at a preliminary stage and subject to adjustments. Despite these reports, Musk stated on the social media platform X that xAI is not actively seeking additional funding. Musk asserted that the company has plenty of capital. Meanwhile, a fresh report has emerged that another venture of Musk, SpaceX, is planning to invest $2bn in xAI. This is part of a $5bn equity funding round, according to The Wall Street Journal. This move further intertwines Musk's ventures, including SpaceX, Tesla, and X. In June 2025, Morgan Stanley announced that xAI secured $5bn through debt issuance, accompanied by an equivalent amount in a strategic equity investment. These funds are intended to bolster xAI's AI infrastructure through expanded data centres amid increasing competition in the sector. Earlier in 2025, xAI acquired Musk's social media platform X, formerly known as Twitter. The acquisition X at $33bn while pegging xAI at $80bn. This merger enabled the integration of xAI's Grok chatbot into various applications such as Starlink support and potentially into Tesla's Optimus robots in the future. In late May, xAI reportedly forged a partnership with Telegram to incorporate the Grok chatbot across all the apps of the messaging service. Under this agreement, xAI will compensate Telegram with $300m through cash and equity while sharing half of any subscription revenue generated via the platform. Overall, financial projections from Morgan Stanley suggest that xAI could achieve over $13bn in annual earnings by 2029, as per a report in Bloomberg News. By the end of 2025, the AI company is anticipated to generate $1bn in gross revenue while allocating $18bn for investments in data centre expansion. "Musk's xAI plans funding round targeting up to $200bn" was originally created and published by Verdict, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store